Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dianthus Therapeutics (DNTH) Research & Development (2017 - 2025)

Dianthus Therapeutics has reported Research & Development over the past 8 years, most recently at $32.5 million for Q3 2025.

  • Quarterly results put Research & Development at $32.5 million for Q3 2025, up 27.19% from a year ago — trailing twelve months through Sep 2025 was $117.0 million (up 78.62% YoY), and the annual figure for FY2024 was $87.9 million, up 167.65%.
  • Research & Development for Q3 2025 was $32.5 million at Dianthus Therapeutics, up from $26.3 million in the prior quarter.
  • Over the last five years, Research & Development for DNTH hit a ceiling of $32.5 million in Q3 2025 and a floor of -$9.0 million in Q4 2022.
  • Median Research & Development over the past 4 years was $13.1 million (2024), compared with a mean of $15.5 million.
  • Biggest five-year swings in Research & Development: tumbled 64.66% in 2023 and later soared 255.4% in 2024.
  • Dianthus Therapeutics' Research & Development stood at -$9.0 million in 2022, then soared by 197.78% to $8.8 million in 2023, then soared by 255.4% to $31.2 million in 2024, then increased by 4.1% to $32.5 million in 2025.
  • The last three reported values for Research & Development were $32.5 million (Q3 2025), $26.3 million (Q2 2025), and $27.0 million (Q1 2025) per Business Quant data.